The overall tolerance to the treatment was very good. The main toxicity during concomitant therapy was myelosuppression. Another PcP was observed in a pt with an unresected tumor receiving high doses of corticosteroids. Only 6 pts have died to date. Updated results will be presented.
Subjective toxicity is mild, severe myelosuppression with thrombocytopenia and neutropenia is rare.
An international randomized trial of this regimen compared to standard RT will be activated in January 2000.